- Home
- AIRG vs KPTI Comparison
AIRG vs KPTI Comparison
Compare AIRG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRG
- KPTI
- Stock Information
- Founded
- AIRG 1995
- KPTI 2008
- Country
- AIRG United States
- KPTI United States
- Employees
- AIRG N/A
- KPTI N/A
- Industry
- AIRG Radio And Television Broadcasting And Communications Equipment
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- AIRG Technology
- KPTI Health Care
- Exchange
- AIRG Nasdaq
- KPTI Nasdaq
- Market Cap
- AIRG 48.7M
- KPTI 44.5M
- IPO Year
- AIRG 2016
- KPTI 2013
- Fundamental
- Price
- AIRG $3.98
- KPTI $4.27
- Analyst Decision
- AIRG Strong Buy
- KPTI Buy
- Analyst Count
- AIRG 2
- KPTI 6
- Target Price
- AIRG $9.25
- KPTI $48.50
- AVG Volume (30 Days)
- AIRG 11.7K
- KPTI 86.5K
- Earning Date
- AIRG 05-07-2025
- KPTI 05-12-2025
- Dividend Yield
- AIRG N/A
- KPTI N/A
- EPS Growth
- AIRG N/A
- KPTI N/A
- EPS
- AIRG N/A
- KPTI N/A
- Revenue
- AIRG $58,381,000.00
- KPTI $142,126,000.00
- Revenue This Year
- AIRG N/A
- KPTI $2.34
- Revenue Next Year
- AIRG $23.54
- KPTI $13.81
- P/E Ratio
- AIRG N/A
- KPTI N/A
- Revenue Growth
- AIRG 8.46
- KPTI 1.19
- 52 Week Low
- AIRG $3.17
- KPTI $3.51
- 52 Week High
- AIRG $10.34
- KPTI $17.40
- Technical
- Relative Strength Index (RSI)
- AIRG 49.56
- KPTI 35.16
- Support Level
- AIRG $3.85
- KPTI $4.33
- Resistance Level
- AIRG $4.35
- KPTI $4.65
- Average True Range (ATR)
- AIRG 0.20
- KPTI 0.47
- MACD
- AIRG -0.00
- KPTI -0.12
- Stochastic Oscillator
- AIRG 36.33
- KPTI 8.95
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.